10 January 2020

ProQR Aurora Clinical Trial: Phase 1/2 “Safety and Efficacy Study” for Autosomal Dominant Retinitis Pigmentosa

ProQR Therapeutics are conducting an ongoing clinical trial to investigate the safety and tolerability of QR-1123 in individuals living with Autosomal Dominant Retinitis Pigmentosa, due to the P23H mutation in the RHO gene.

Aurora is a 12-month trial designed to assess if differing doses of investigational gene therapy QR-1123 are safe, as well as to determine whether or not they elicit any improvements in visual function or retinal structure. Participants in the study receive a single intravitreal injection or as many as 4 doses and the effects of these treatments will be measured to confirm a safe and effective therapeutic dose.

ProQR have a page on their website describing the Aurora clinical trial, rationale and design, along with other links to get additional details about Aurora. Click here to learn more about the Aurora phase 1/2 clinical trial and what this trial means for people living with Autosomal Dominant Retinitis Pigmentosa.

Join Our Mailing List

To keep up to date with our news and activities, please complete this simple form

Retina International
Ausstellungsstr. 36
8005 Zurich
Switzerland

Follow Us
Twitter
Youtube

This site has been supported through an unrestricted educational grant from Novartis

Novartis
Font Resize
High Contrast